January 1st is a Good Time to Evaluate Funding Options

A New Year Can Mean New Funding Challenges For Your Patients

At Onco360 we see the benefit reset on January 1 as an opportunity to revisit funding solutions for new and existing patients now – and all year long.

Dedicated to helping Your Medicare Patients Through the Donut Hole

Adherence is important when it comes to a cancer treatment plan, and financial challenges can often interrupt therapy. Onco360 can help with over 20 OncoAdvocate® associates dedicated to finding funding opportunities all year for qualified patients.

In fact, in 2022, 74% of patients have ZERO out-of-pocket costs with a projected
$320 million secured from third-party funding.

Watch our video below to see how Onco360 can help to lessen the financial burden of the Medicare donut hole.

Why Choose Onco360 for your Medicare Patients?

  • Our one-of-a-kind Funding FastTrack system searches for available funding assistance multiple times a day. When there is a match, patients are matched quickly with available funding options.
  • Funding solutions for patients affected by the discontinuation of Free Drug Programs such as Zytiga and Xeloda.
  • A robust portfolio of 100+ limited distribution and generic medications including Lenalidomide and Abiraterone. 
  • Blister packaging is available – even for generic medications.
  • #1 in patient and provider satisfaction*

You Don’t Have to Choose the Pharmacy Listed on the Back of a
Patient’s Insurance Card.

According to the Medicare Part D Statute, “any” pharmacy that is willing and able to meet a Medicare Part D plan’s standard terms and conditions, must be considered an “in-network” pharmacy provider. Watch our video to learn more.


Partner with the oncology experts at Onco360 for your Medicare Part D patients.

We can help ease financial burden and adherence issues at the beginning of the year and all your long. After all, our number one priority is the same as yours – better patient care.

Refer Today

Limited Distribution Oncology Medications


Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis



Order Forms

*Third-party survey data provided by MMIT for Independent Specialty Pharmacies (Oncology). Report dates Q3 and Q4 2021.